Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
about
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
description
A clinical trial related to cancer immunotherapy, retrieved from clinicaltrials.gov
@en
klinisch onderzoek
@nl
name
Lung-MAP: Durvalumab as Second ...... cer and No Matching Biomarkers
@en
Lung-MAP: Durvalumab as Second ...... cer and No Matching Biomarkers
@nl
type
label
Lung-MAP: Durvalumab as Second ...... cer and No Matching Biomarkers
@en
Lung-MAP: Durvalumab as Second ...... cer and No Matching Biomarkers
@nl
prefLabel
Lung-MAP: Durvalumab as Second ...... cer and No Matching Biomarkers
@en
Lung-MAP: Durvalumab as Second ...... cer and No Matching Biomarkers
@nl
P6153
P3098
NCT02766335